Key Trends in Transcatheter Tricuspid Valve Interventions
Key Trends in Transcatheter Tricuspid Valve Interventions – Summary
1. AHA Recognition: The AHA highlighted discussions on transcatheter tricuspid interventions from the CRT 2025 meeting.
2. Historical Neglect: Tricuspid valve disease has been underdiagnosed and undertreated, as it was previously assumed that mitral valve treatment would indirectly improve tricuspid regurgitation.
3. Growing Interest in Percutaneous Interventions: Recent data show the need for direct intervention, leading to improved surgical outcomes and increased focus on transcatheter approaches.
4. Transcatheter Annuloplasty Rings: While widely used in surgery, these rings are not yet available for transcatheter procedures. There is an increasing demand for a percutaneous annuloplasty device, with promising developments like the Amend device.
5. Challenges in Imaging and Deployment: The main obstacles in transcatheter annuloplasty development include imaging difficulties and ease of device deployment.
6. Clinical Efficacy Limitations: Unlike TAVR, tricuspid interventions lack strong mortality data, relying mostly on quality-of-life (QOL) improvements rather than hard clinical endpoints.
7. Device Limitations: Current transcatheter options (Abbott’s TriClip, Edwards’ Evoque valve) were adapted from mitral valve technologies, but the tricuspid valve’s unique anatomy presents durability and imaging challenges.
8. Second-Generation Devices: CRT 2025 introduced new transcatheter devices specifically designed for the tricuspid valve, marking a shift toward dedicated solutions.
9. Increasing Procedural Volumes: Growing awareness and technological advancements are expanding access to tricuspid interventions, benefiting more patients.